ConSynance Joins the Prader-Willi Syndrome Clinical Trial Consortium
11 mars 2019 09h00 HE
|
ConSynance Therapeutics, Inc.
Rensselaer, New York., March 11, 2019 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc., a clinical-stage biotechnology company developing two innovative treatments for Prader-Willi Syndrome (PWS),...
ConSynance Presents CSTI-100 Data at NASH Conference
27 sept. 2018 09h00 HE
|
ConSynance Therapeutics, Inc.
Rensselaer, New York., Sept. 27, 2018 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc. announced today that Peter Guzzo, Ph.D., CEO, gave an oral presentation regarding the company's Phase I...